Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ:GILD)

119.87 -0.15 (-0.12%)
Streaming Delayed Price Updated: 1:46 PM EDT, Aug 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Gilead Sciences

< Previous 1 2 3 4 5 6 7 8 9
...
63 64 Next >
Trodelvy® Plus Keytruda® Reduces Risk of Disease Progression or Death by 35% Versus Keytruda and Chemotherapy in First-Line PD-L1+ Metastatic Triple-Negative Breast Cancer
From Gilead Sciences, Inc.
Via Business Wire
BioLineRx Stock Jumps On Positive Data from Pilot Phase Of Pancreatic Cancer Drug Trial: Retail Cheers The ‘Buy’ Rating
The company said that updated results from the pilot phase indicate that four of eleven patients remained disease progression-free after more than one year. 
Via Stocktwits
Gilead Eyes HIV Drug Rollout In Low-Income Countries Despite Funding Uncertainty, Says Report: Retail Holds Onto Bearish Stance
Gilead Chief Commercial Officer Johanna Mercier told Reuters that the company is eyeing a “global approach" to the launch of Lenacapavir. 
Via Stocktwits
Topics Government
GILEAD SCIENCES INC (NASDAQ:GILD) – A Quality Stock Worth Considering
GILEAD SCIENCES (NASDAQ:GILD) is a high-quality biopharma stock with strong profitability, efficient capital use, and attractive valuation, making it a candidate for long-term investors. 
Via Chartmill
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
GILEAD SCIENCES INC (NASDAQ:GILD) – A Potentially Undervalued Biopharmaceutical Stock
GILEAD SCIENCES (NASDAQ:GILD) appears undervalued with strong profitability, a solid dividend, and reasonable growth potential, making it a candidate for value investors. 
Via Chartmill
ASCENT-03: Trodelvy® Demonstrates Highly Statistically Significant & Clinically Meaningful Improvement in Progression Free Survival in Patients With First-line Metastatic Triple-Negative Breast Cancer Who Are Not Candidates for Checkpoint Inhibitors
From Gilead Sciences, Inc.
Via Business Wire
What Analysts Are Saying About Gilead Sciences Stock
 
Via Benzinga
What's going on in today's session: S&P500 movers
Curious about the top performers within the S&P500 index one hour before the close of the markets on Monday? Dive into the list of today's session's top gainers and losers for a comprehensive... 
Via Chartmill
Uncover the latest developments among S&P500 stocks in today's session.
Curious about the top performers within the S&P500 index in the middle of the day on Monday? Dive into the list of today's session's top gainers and losers for a comprehensive overview. 
Via Chartmill
Gilead and Kite Announce Presentation of Transformative Data in 1L Metastatic Triple-Negative Breast Cancer, Updated Results in Multiple Myeloma and Early Data From Novel Investigational CAR T-Cell Therapy Targeting Brain Cancer at 2025 ASCO and EHA
From Gilead Sciences, Inc.
Via Business Wire
Is the Market Bullish or Bearish on Gilead Sciences?
 
Via Benzinga
Thermo Fisher, Biogen, Gilead Sciences, Moderna, and QuidelOrtho Stocks Trade Up, What You Need To Know
A number of stocks jumped in the afternoon session after the major indices popped (Nasdaq +3.4%, S&P 500 +2.5%) in response to the positive outcome of U.S.-China trade negotiations, as both sides... 
Via StockStory
Topics Government Stocks World Trade
Top S&P500 movers in Monday's pre-market session
Stay updated with the S&P500 stocks that are on the move in today's pre-market session. 
Via Chartmill
S&P 500, Dow Jones Pharma Stocks Boomerang As Trump Threatens Drug-Price Reform
It's still unclear how President Donald Trump plans to tie drug prices in the U.S. to international prices. 
Via Investor's Business Daily
Topics Government Stocks
Wall Street Rips Higher As Tariff Truce Halts US–China Economic Escalation
US-China agree to slash tariffs by over 100%, easing fears of economic slowdown and inflation. Markets cheer with futures rising and yields up. 
Via Benzinga
Topics Economy World Trade
GILD Q1 Earnings Call: HIV Growth and Pipeline Momentum Offset Revenue Miss
Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) missed Wall Street’s revenue expectations in Q1 CY2025, with sales flat year on year at $6.67 billion. The company’s full-year revenue guidance... 
Via StockStory
2 High-Yield Dividend Stocks to Buy in May and Hold Forever
Via The Motley Fool
Topics Intellectual Property
Market Monitor May 9 (Boeing, MicroStrategy UP - Match Group DOWN)
U.S. stocks rally amid steady Fed rates, strong Disney and AMD earnings, but Alphabet falls on Apple concerns. 
Via Chartmill
Topics Economy
3 Value Stocks with Mounting Challenges
Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The key risk, however, is that these stocks are... 
Via StockStory
Final Data From the Phase 3 MYR301 Study Demonstrated Longer Treatment With Bulevirtide Was Associated With Sustaining Undetectability After Stopping Treatment
From Gilead Sciences, Inc.
Via Business Wire
Marjorie Taylor Greene Goes Stock Shopping Again: Here Are 50+ Stocks The Congresswoman Bought
Marjorie Taylor Greene disclosed buying more than 50 stocks in early May. A look at the list and why the congresswoman's past trades have drawn red flags. 
Via Benzinga
Gilead’s Livdelzi® (Seladelpar) Demonstrated Consistent Efficacy and Safety Regardless of Prior Treatment History in New Data Presented at EASL 2025
From Gilead Sciences, Inc.
Via Business Wire
Market Monitor May 7 ( Hims & Hers Health, Upwork UP - Palantir, Monderna DOWN)
Markets slide on vaccine regulation fears, trade uncertainty, and cautious earnings despite strong tech and consumer stock moves. 
Via Chartmill
GILEAD SCIENCES INC (NASDAQ:GILD) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
When you look at GILEAD SCIENCES INC (NASDAQ:GILD), it's hard to ignore the strong fundamentals, especially considering its likely undervaluation. 
Via Chartmill
1 Profitable Stock on Our Watchlist and 2 to Turn Down
While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my... 
Via StockStory
3 Biotech Giants Gaining From U.S. Sales and Policy Shifts
The significant domestic revenue base of select US biotech companies offers stability potential for investors navigating global trade complexities. 
Via MarketBeat
Topics Economy World Trade
Gilead Sciences Inc (NASDAQ:[GILD](https://www.chartmill.com/stock/quote/GILD)): A Dividend Stock Worth Considering
Gilead Sciences Inc (NASDAQ:[GILD](https://www.chartmill.com/stock/quote/GILD)): A Dividend Stock Worth Considering 
Via Chartmill
These 3 Funds Offer Sky-High Yields of 15% or More and Trade at a Discount
Via The Motley Fool
Moderna (MRNA) Reports Earnings Tomorrow: What To Expect
Biotechnology company Moderna (NASDAQ:MRNA) will be announcing earnings results tomorrow before market hours. Here’s what you need to know. 
Via StockStory
Topics Artificial Intelligence World Trade
< Previous 1 2 3 4 5 6 7 8 9
...
63 64 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.